BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 19758222)

  • 1. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
    Popa C; Leandro MJ; Cambridge G; Edwards JC
    Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cells, be gone--B-cell depletion in the treatment of rheumatoid arthritis.
    Tsokos GC
    N Engl J Med; 2004 Jun; 350(25):2546-8. PubMed ID: 15201410
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
    De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
    Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell-directed therapy in rheumatoid arthritis--clinical experience.
    Panayi GS
    J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
    Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
    Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
    Silverman GJ
    Arthritis Rheum; 2006 Aug; 54(8):2356-67. PubMed ID: 16868991
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab for the treatment of rheumatoid arthritis.
    Schuna AA
    Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
    Jacobi AM; Dörner T
    Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.